Harvard Medical School
25 Shattuck Street
Boston
Massachusetts
02115
United States
Tel: 617-432-1000
Website: http://www.hms.harvard.edu/
553 articles with Harvard Medical School
-
Spaulding Rehabilitation Hospital and Highland Instruments, Inc., Jointly Announce National Institutes of Health Funded Clinical Trial Investigating Highland's Electrosonic Stimulation Technology to Treat Carpal Tunnel Syndrome
11/28/2022
Spaulding Rehabilitation Hospital, a teaching affiliate of Harvard Medical School, and Highland Instruments, Inc., jointly announced the advancement into Phase II of their National Institutes of Health funded Clinical Trial investigating Highland Instruments' Electrosonic Stimulation, a novel noninvasive brain stimulation technology, to treat Carpal Tunnel Syndrome1.
-
Sensorium Therapeutics, which closed a $30 million Series A Tuesday, is embracing the complexity of neuropsychiatric diseases with nature-inspired psychoactive medicines.
-
Novavax seeks EUA for COVID-19 Booster, a 100-year-old TB vaccine may protect against the disease and public health officials struggle with fall planning.
-
COVID-19 is much more than a respiratory illness, and many of its longer-term effects and secondary issues are often puzzling. For that and more research news, continue reading.
-
Researchers from Harvard Medical School have published data in Science Daily involving the role of T cells in autoimmune diseases.
-
Although COVID-19 appears to be on the run in the U.S., there is still a threat of resurgence. Here’s a look at some of the most recent COVID-19 stories and research.
-
Despite the refutation of research articles by Piero Anversa, they continue to serve as a basis for funding requests from scientists who hope to prove that the heart can regenerate cardiac muscle.
-
South San Francisco-based Rigel Pharmaceuticals reported its Phase III Forward trial of fostamatinib did not show statistical significance in warm autoimmune hemolytic anemia
-
While tools to reverse age-related cellular dysfunction haven’t yet reached the masses, two research studies have emerged this week that hint at progress.
-
Pancreatic transplants are difficult to pull off for Type 1 diabetes, but new technology may make it possible, and infusions of spinal fluid from young mice to older ones reportedly reverses memory loss.
-
Here's a look at some of this week's most interesting research news.
-
With $67 million in Series A financing, newly-launched Apertura plans to develop genetic medicines using technologies that address key limitations of gene delivery and expression.
-
Seismic Therapeutic, Inc. announced its launch and financing of $101 million to fund two new programs and further develop its existing IMPACT™ platform.
-
A recent study has highlighted the need for more stringent Phase II trial protocols on the basis that over 80% of candidate oncology treatments that go into Phase III failed to achieve OS goals.
-
Intra-Cellular Therapies published its Study 404 Phase III trial of lumateperone as monotherapy for major depressive episodes associated with bipolar I or bipolar II disorder.
-
The massive genetic data mining project aims to gain deeper insight into how human genetic variants affect risk for common complex diseases.
-
The approval was built on data from the Phase III ASPEN trial that compared Brukinsa to ibrutinib in a total of 201 patients. Here's more about the drug.
-
New data is coming out every day about COVID-19 and the body’s response to vaccines. Here’s a look at some of the top stories.
-
The company also issued an open letter to the Alzheimer’s disease community from Alfred Sandrock, which attempts to push back against negative media attention.
-
As part of the announcement, TRexBio indicated that Johnston Erwin had been appointed CEO and Ovid Trifan would be the company’s CMO.